Show simple item record

dc.contributor.authorPadrón-Barthe, Laura
dc.contributor.authorVillalba-Orero, María
dc.contributor.authorGómez-Salinero, Jesús M.
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorRomán, Marta
dc.contributor.authorLarrasa-Alonso, Javier
dc.contributor.authorOrtiz-Sánchez, Paula
dc.contributor.authorMartínez, Fernando
dc.contributor.authorLópez-Olañeta, Marina
dc.contributor.authorBonzón-Kulichenko, Elena
dc.contributor.authorVázquez, Jesús
dc.contributor.authorMartí-Gómez, Carlos
dc.contributor.authorSantiago, Demetrio J.
dc.contributor.authorPrados, Belén
dc.contributor.authorGiovinazzo, Giovanna
dc.contributor.authorGómez-Gaviro, María Victoria
dc.contributor.authorPriori, Silvia
dc.contributor.authorGarcía Pavía, Pablo 
dc.contributor.authorLara-Pezzi, Enrique
dc.description.abstractBACKGROUND: Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in heart failure and sudden cardiac death. The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (transmembrane protein 43). The function and localization of TMEM43 are unknown, as is the mechanism by which the p.S358L mutation causes the disease. Here, we report the characterization of the first transgenic mouse model of ARVC5. METHODS: We generated transgenic mice overexpressing TMEM43 in either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal cardiomyocytes under the control of the α-myosin heavy chain promoter. RESULTS: We found that mice expressing TMEM43-S358L recapitulate the human disease and die at a young age. Mutant TMEM43 causes cardiomyocyte death and severe fibrofatty replacement. We also demonstrate that TMEM43 localizes at the nuclear membrane and interacts with emerin and β-actin. TMEM43-S358L shows partial delocalization to the cytoplasm, reduced interaction with emerin and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). Furthermore, we show that targeting cardiac fibrosis has no beneficial effect, whereas overexpression of the calcineurin splice variant calcineurin Aβ1 results in GSK3β inhibition and improved cardiac function and survival. Similarly, treatment of TMEM43 mutant mice with a GSK3β inhibitor improves cardiac function. Finally, human induced pluripotent stem cells bearing the p.S358L mutation also showed contractile dysfunction that was partially restored after GSK3β inhibition. CONCLUSIONS: Our data provide evidence that TMEM43-S358L leads to sustained cardiomyocyte death and fibrofatty replacement. Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical GSK3β inhibition improves cardiac function and increases mice life span. Our results pave the way toward new therapeutic approaches for
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.titleSevere Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β.spa
dc.description.extent3610 KBspa

Files in this item

2.- Severe Cardiac Dysfunction.pdf3.524MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España